AMARIN CORPORATION PLC

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

08 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

10 июн 2024 14:19:27 Источник NetDania Notify

Amarin Board of Directors Announces CEO Transition

04 июн 2024 06:30:00 Источник Nasdaq GlobeNewswire

 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

28 май 2024 07:15:23 Источник Nasdaq GlobeNewswire

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

06 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

 Amarin Reports First Quarter 2024 Business Update and Financial Results

01 май 2024 06:00:00 Источник Nasdaq GlobeNewswire

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

24 апр 2024 13:00:01 Источник Nasdaq GlobeNewswire

Amarin Announces Results of Annual General Meeting of Shareholders

22 апр 2024 07:00:25 Источник Nasdaq GlobeNewswire

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

15 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

08 апр 2024 07:00:01 Источник Nasdaq GlobeNewswire

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

06 апр 2024 14:30:00 Источник Nasdaq GlobeNewswire

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

03 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

25 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

15 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Amarin Chairman & CEO Issue Letter to Shareholders

22 янв 2024 06:30:00 Источник Nasdaq GlobeNewswire

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

10 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

11 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Amarin Reports Third Quarter 2023 Financial Results

01 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

31 окт 2023 11:00:00 Источник Nasdaq GlobeNewswire